Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors

Molecular Carcinogenesis

Volumn 54, Issue 11, 2015, Pages 1376-1386

  Woerner, Stefan M ^a,c   Tosti, Elena ^b   Yuan, Yan P ^c   Kloor, Matthias ^a,c,d   Bork, Peer ^c   Edelmann, Winfried ^b   Gebert, Johannes ^a,c,d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d Clinical Cooperation Unit Applied Tumor Biology   (Germany)

Author keywords

Coding microsatellite instability; MMR deficient mice; MSI intestinal carcinogenesis; MSI target genes

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FRAMESHIFT MUTATION; GENE SEQUENCE; HUMAN; INDEL MUTATION; INTESTINE TUMOR; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BASE MISPAIRING; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER;

DNA BINDING PROTEIN; MICROSATELLITE DNA;

ANIMALS; BASE PAIR MISMATCH; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; FRAMESHIFT MUTATION; HUMANS; INTESTINAL NEOPLASMS; MICE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS;

EID: 84945437544     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22213     Document Type: Article

References (45)

1. Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem 2006; 281:30305-30309.
2. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999; 59:2029-2033.
3. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75:1027-1038.
4. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75:1215-1225.
5. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368:258-261.
6. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263:1625-1629.
7. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138:2073-2087.
8. Biswas S, Trobridge P, Romero-Gallo J, et al. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Genes Chromosomes Cancer 2008; 47:95-106.
9. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 2000; 97:10872-10877.
10. Hempen PM, Zhang L, Bansal RK, et al. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res 2003; 63:994-999.
11. Edelmann L, Edelmann W. Loss of DNA mismatch repair function and cancer predisposition in the mouse: Animal models for human hereditary nonpolyposis colorectal cancer. Am J Med Genet 2004; 129C:91-99.
12. Reitmair AH, Schmits R, Ewel A, et al. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 1995; 11:64-70.
13. Baker SM, Plug AW, Prolla TA, et al. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat Genet 1996; 13:336-342.
14. Prolla TA, Baker SM, Harris AC, et al. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 1998; 18:276-279.
15. de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995; 82:321-330.
16. Edelmann W, Cohen PE, Kane M, et al. Meiotic pachytene arrest in MLH1-deficient mice. Cell 1996; 85:1125-1134.
17. Lin DP, Wang Y, Scherer SJ, et al. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res 2004; 64:517-522.
18. Edelmann W, Umar A, Yang K, et al. The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res 2000; 60:803-807.
19. Wei K, Clark AB, Wong E, et al. Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. Genes Dev 2003; 17:603-614.
20. Edelmann W, Yang K, Umar A, et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997; 91:467-477.
21. Yang G, Scherer SJ, Shell SS, et al. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 2004; 6:139-150.
22. Andrew SE, Xu XS, Baross-Francis A, et al. Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts. Carcinogenesis 2000; 21:1291-1295.
23. Schrader CE, Edelmann W, Kucherlapati R, Stavnezer J. Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes. J Exp Med 1999; 190:323-330.
24. Péron S, Metin A, Gardès P, et al. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 2008; 205:2465-2472.
25. Narayanan L, Fritzell JA, Baker SM, Liskay RM, Glazer PM. Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2. Proc Natl Acad Sci USA 1997; 94:3122-3127.
26. Yao X, Buermeyer AB, Narayanan L, et al. Different mutator phenotypes in Mlh1- versus Pms2-deficient mice. Proc Natl Acad Sci USA 1999; 96:6850-6855.
27. Kucherlapati MH, Lee K, Nguyen AA, et al. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology 2010; 138:993-1002.
28. Lowsky R, Magliocco A, Ichinohasama R, et al. MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability. Blood 2000; 95:1767-1772.
29. Edelmann W, Yang K, Kuraguchi M, et al. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res 1999; 59:1301-1307.
30. Kabbarah O, Mallon MA, Pfeifer JD, Edelmann W, Kucherlapati R. A panel of repeat markers for detection of microsatellite instability in murine tumors. Mol Carcinogen 2003; 38:155-159.
31. Bacher JW, Abdel Megid WM, Kent-First MG, Halberg RB. Use of mononucleotide repeat markers for detection of microsatellite instability in mouse tumors. Mol Carcinogen 2005; 44:285-292.
32. Woerner SM, Gebert J, Yuan YP, et al. Systematic identification of genes with coding microsatellites mutated in DNA mismatch repair-deficient cancer cells. Int J Cancer 2001; 93:12-19.
33. Woerner SM, Benner A, Sutter C, et al. Pathogenesis of DNA repair-deficient cancers: A statistical meta-analysis of putative real common target genes. Oncogene 2003; 22:2226-2235.
34. Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork P. SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res 2010; 38:D682-689.
35. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248-5257.
36. Buhard O, Cattaneo F, Wong YF, et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol 2006; 24:241-251.
37. Berger AH, Pandolfi PP. Haplo-insufficiency: A driving force in cancer. J Pathol 2011; 223:137-146.
38. Lichti-Kaiser K, ZeRuth G, Kang HS, et al. Gli-similar proteins: Their mechanisms of action, physiological functions, and roles in disease. Vitam Horm 2012; 88:141-171.
39. Scanlan MJ, Chen YT, Williamson B, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998; 76:652-658.
40. Bi X, Jones T, Abbasi F, et al. Drosophila caliban, a nuclear export mediator, can function as a tumor suppressor in human lung cancer cells. Oncogene 2005; 24:8229-8239.
41. Carbonnelle D, Jacquot C, Lanco X, et al. Up-regulation of a novel mRNA (NY-CO-1) involved in the methyl 4-methoxy-3-(3-methyl-2-butenoyl) benzoate (VT1)-induced proliferation arrest of a non-small-cell lung carcinoma cell line (NSCLC-N6). Int J Cancer 2001; 92:388-397.
42. Hattersley N, Shen L, Jaffray EG, Hay RT. The SUMO protease SENP6 is a direct regulator of PML nuclear bodies. Mol Biol Cell 2011; 22:78-90.
43. Mukhopadhyay D, Dasso M. The fate of metaphase kinetochores is weighed in the balance of SUMOylation during S phase. Cell Cycle 2010; 9:3194-3201.
44. Lockwood WW, Thu KL, Lin L, et al. Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clin Cancer Res 2012; 18:1936-1946.
45. Kim YR, Song SY, Kim SS, An CH, Lee SH, Yoo NJ. Mutational and expressional analysis of RFC3, a clamp loader in DNA replication, in gastric and colorectal cancers. Hum Pathol 2010; 41:1431-1437.